WallStreetZenWallStreetZen

NASDAQ: TRDA
Entrada Therapeutics Inc Earnings Dates, Reports, Calls

OverviewForecastEarnings
RevenueDividendOwnership
Entrada Therapeutics earnings were $24.8M for the trailing 12 months ending Mar 31, 2025, with 15.7% growth year over year. The latest TRDA earnings report on Mar 31, 2025 announced Q1 2025 earnings of -$17.3M, down 1,634% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, TRDA reported annual earnings of $65.6M, with -1,081.7% growth.

TRDA past earnings growth

How has TRDA's earnings growth performed historically?

Company
15.71%
Industry
11.53%
Market
34%
TRDA's earnings have grown faster... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
TRDA's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Market Performance
TRDA's earnings growth is accelerating... subscribe to Premium to read more.
Accelerating Earnings Growth Performance

TRDA earnings history

Current Revenue
$172.2M
Current Earnings
$24.8M
Current Profit Margin
14.4%

TRDA Return on Equity

Current Company
5.8%
Current Industry
-60.2%
Current Market
31.5%
TRDA's Return on Equity (5.8%)... subscribe to Premium to read more.
High Return on Equity Performance

TRDA undefined

Current Company
4.6%
Current Industry
-2.5%
TRDA is generating higher Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when TRDA announces earnings.

TRDA undefined

Current Company
5.09%
Current Industry
5.8%
TRDA has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

TRDA vs Biotech Stocks

TickerEBITDAEarningsY/Y EarningsEPS
TRDA$27.59M$24.78M+15.71%$0.81
XOMA$3.33M-$5.60MN/A-$1.10
OLMA-$127.31M-$128.89MN/A-$1.90
ALLO-$238.37M-$252.32MN/A-$1.23
GOSS-$35.70M-$51.24MN/A-$0.23
View Top Biotech Stocks

Entrada Therapeutics Earnings Reports & History FAQ

What were Entrada Therapeutics's earnings last quarter?

On TRDA's earnings call on Invalid Date, Entrada Therapeutics (NASDAQ: TRDA) reported Q1 2025 earnings per share (EPS) of -$0.42, up 160% year over year. Total TRDA earnings for the quarter were -$17.35 million. In the same quarter last year, Entrada Therapeutics's earnings per share (EPS) was $0.70.

If you're new to stock investing, here's how to buy Entrada Therapeutics stock.

Is Entrada Therapeutics profitable or losing money?

As of the last Entrada Therapeutics earnings report, Entrada Therapeutics is currently profitable. Entrada Therapeutics's net profit (also called net income) for the twelve months ending Mar 31, 2025 was $24.78 million, a 5.52% increase year over year.

What was TRDA's earnings growth in the past year?

As of Entrada Therapeutics's earnings date in Invalid Date, Entrada Therapeutics's earnings has grown 15.71% year over year. This is 4.18 percentage points higher than the US Biotechnology industry earnings growth rate of 11.53%. TRDA earnings in the past year totalled $24.78 million.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.